Blood biomarkers to guide stroke thrombolysis

Frontiers in Bioscience - Elite

Volumn 1 E, Issue 1, 2009, Pages 200-208

  Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Biomarkers; Hemostasis; Intracerebral hemorrhage; Metalloproteinases; Pharmacogenomics; Plasmin; Proteomics; Review; Stroke; Thrombolysis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGENASE 3; GELATINASE B; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD; BRAIN HEMORRHAGE; FIBRINOLYTIC THERAPY; HUMAN; METABOLISM; METHODOLOGY; REVIEW; STROKE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INTRACRANIAL HEMORRHAGES; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 71449128134     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Reynolds M. A., H. J. Kirchick, J. R. Dahlen, J. M. Anderberg, P. H. McPherson, K. K. Nakamura, D. T. skowitz, G. E. Valkirs & K. F. Buechler: Early biomarkers of stroke. Clin Chem, 49, 1733-9 (2003) (Pubitemid 37194242)
2. H J. R., R. Blessing, W. D. White, H. P. Grocott, M. F. Newman & D. T. Laskowitz: Novel diagnostic test for acute stroke. Stroke, 35, 57-63 (2004) (Pubitemid 38057590)
3. Allard L., P. R. Burkhard, P. Lescuyer, J. A. Burgess, N. Walter, D. F. Hochstrasser & J. C. Sanchez: PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem, 51, 2043-51 (2005) (Pubitemid 41532619)
4. Foerch C., I. Curdt, B. Yan, F. Dvorak, M. Hermans, J. Berkefeld, A. Raabe, T. Neumann-Haefelin, H. Steinmetz & M. Sitzer: Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry, 77, 181-4 (2006) (Pubitemid 43220838)
5. Delgado P., J. Alvarez-Sabin, M. Ribo, F. Purroy, A. Rossell, A. Penalba, I. Fernández-Cadenas, J. F. Arenillas, C. A. Molina & J. Montaner: Differentiating ischemic and hemorrhagic stroke by means of a panel of plasma biomarkers. Cerebrovasc Dis, 19(suppl 2), 63 (2005)
6. Allard L., P. Lescuyer, J. Burgess, K. Y. Leung, M. Ward, N. Walter, P. R. Burkhard, G. Corthals, D. F. Hochstrasser & J. C. Sanchez: ApoC-I and ApoCIII as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics, 4, 2242-51 (2004) (Pubitemid 39025324)
7. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 333, 1581-7 (1995)
8. Heuschmann P. U., K. Berger, B. Misselwitz, P. Hermanek, C. Leffmann, M. Adelmann, H. J. Buecker-Nott, J. Rother, B. Neundoerfer & P. L. Kolominsky-Rabas; German Stroke Registers Study Group; Competence Net Stroke: Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke, 34, 1106-13 (2003)
9. Tanne D., S. E. Kasner, A. M. Demchuk, N. Koren-Morag, S. Hanson, M. Grond & S. R. Levine: Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation, 105, 1679-85 (2002) (Pubitemid 34298612)
10. The NINDS t-PA Stroke Study Group: Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke, 28, 2109-18 (1997)
11. Larrue V., R. von Kummer, G. del Zoppo & E. Bluhmki: Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke, 28, 957-60 (1997) (Pubitemid 27209140)
12. Kidwell C. S., J. L. Saver, J. P. Villablanca, G. Duckwiler, A. Fredieu, K. Gough, M. C. Leary, S. Starkman, Y. P. Gobin, R. Jahan, P. Vespa, D. S. Liebeskind, J. R. Alger & F. Vinuela: Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. Stroke, 33, 95-98 (2002) (Pubitemid 34052192)
13. Alexandrov A. V., S. E. Black, L. E. Ehrlich, C. B. Caldwell & J. W. Norris: Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. Stroke, 28, 1198-1202 (1997) (Pubitemid 27248896)
14. Wang X., K. Tsuji, S. R. Lee, M. Ning, K. L. Furie, A. M. Buchan & E. H. Lo: Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke, 35, 2726-30 (2004) (Pubitemid 39458380)
15. Petty M. A. & E. H. Lo: Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol, 68, 311-23 (2002) (Pubitemid 36071509)
16. Lo E. H., J. P. Broderick & M. A. Moskowitz: tPA and proteolysis in the neurovascular unit. Stroke, 35, 354-6 (2004) (Pubitemid 38174404)
17. Gasche Y., J. C. Copin, T. Sugawara, M. Fujimura & P. H. Chan: Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab, 21, 1393-1400 (2001) (Pubitemid 33120943)
18. Lo E. H., T. Dalkara & M. A. Moskowitz: Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci, 4, 399-415 (2003) (Pubitemid 37280178)
19. Hamann G. F., Y. Okada & G. J. del Zoppo: Hemorrhagic transformation and microvascular integrity during focal cerebral schemia/reperfusion. J Cereb Blood Flow Metab, 16, 1373-8 (1996) (Pubitemid 26365393)
20. Mun-Bryce S. & G. A. Rosenberg: Matrix metalloproteinases in cerebrovascular disease. J Cerebral Blood Flow Metab, 18, 1163-72 (1998) (Pubitemid 28509829)
21. Asahi M., X. Wang, T. Mori, T. Sumii, J. C. Jung, M. A. Moskowitz, M. E. Fini & E. H. Lo: Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci, 21, 7724-32 (2001) (Pubitemid 32904971)
22. Rosenberg G. A., E. Y. Estrada & J. E. Dencoff: Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke, 29, 2189-95 (1998) (Pubitemid 28443538)
23. Lapchak P. A., D. F. Chapman & J. A. Zivin: Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke, 31, 3034-40 (2000)
24. Tsuji K., T. Auki, E. Tejima, K. Arai, S. R. Lee, D. N. Atochin, P. L. Huang, X. Wang, J. Montaner & E. H. Lo: Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia. Stroke, 36, 1954-9 (2005) (Pubitemid 41266533)
25. Montaner J., J. Alvarez-Sabín, C. Molina, A. Angles, S. Abilleira, J. Arenillas, M. A. Gonzalez & J. Monasterio: Matrix metalloproteinase expression after human cardioembolic stroke. Temporal profile and relation to neurological impairment. Stroke, 32, 1759-66 (2001) (Pubitemid 32772204)
26. Montaner J., J. Alvarez-Sabín, C. Molina, A. Angles, S. Abilleira, J. Arenillas & J. Monasterio: Matrix metalloproteinase (MMP-9) expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke, 32, 2762-7 (2001) (Pubitemid 33134461)
27. Castellanos M., R. Leira, J. Serena, J. M. Pumar, I. Lizasoain, J. Castillo & A. Dávalos: Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke, 34:40-46 (2003)
28. Montaner J., C. A. Molina, J. Monasterio, S. Abilleira, J. F. Arenillas, M. Ribo, M. Quintana & J. Alvarez-Sabin: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation, 107, 598-603 (2003) (Pubitemid 36176811)
29. Montaner J., C. A. Molina, J. F. Arenillas, M. Ribo, R. Huertas, I. Fernández-Cadenas, A. Rosell, A. Penalba, J. Monasterio & J. Alvarez-Sabín: Proteolytic modifications on the metalloproteinase system (MMP-9-Laminin-TIMP-1) induced by t-PA treatment for acute cerebral ischemia in humans. Stroke, 35, 339 (2004)
30. Rosell A., J. Alvarez-Sabin, J. F. Arenillas, A. Rovira, P. Delgado, I. Fernandez-Cadenas, A. Penalba, C. A. Molina & J. Montaner: A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke, 36, 1415-20 (2005) (Pubitemid 40967504)
31. Hynes R. O.: Fibronectins. Sci Am, 254, 42-51 (1986)
32. Peters J. H., L. A. Sporn, M. H. Ginsberg & D. D. Wagner: Human endothelial cells synthesize, process, and secrete fibronectin molecules bearing an alternatively spliced type II homology (ED1). Blood, 75, 1801-8 (1990) (Pubitemid 20161493)
33. Castellanos M., R. Leira, J. Serena, M. Blanco, S. Pedraza, J. Castillo & A. Davalos: Plasma cellularfibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke, 35, 1671-6 (2004) (Pubitemid 38823645)
34. Castellanos M., T. Sobrino, M. Millan, M. Garcia, J. Arenillas, F. Nombela, D. Brea, N. Perez de la Ossa, J. Serena, J. Vivancos, J. Castillo & A. Davalos: Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke, 38, 1855-9 (2007) (Pubitemid 46847259)
35. Foerch C., M. T. Wunderlich, F. Dvorak, M. Humpich, T. Kahles, M. Goertler, J. Alvarez-Sabin, C. W. Wallesch, C. A. Molina, H. Steinmetz, M. Sitzer & J. Montaner: Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke, 38, 2491-5 (2007) (Pubitemid 47329627)
36. Collet J. P., G. Montalescot, E. Vicaut, A. Ankri, F. Walylo, C. Lesty, R. Choussat, F. Beygui, M. Borentain, N. Vignolles & D. Thomas: Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation, 108, 391-4 (2003) (Pubitemid 36935529)
37. Montaner J., M. Ribo, J. Monasterio, C. A. Molina & J. Alvarez-Sabin: Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke, 34, 1038-40 (2003) (Pubitemid 36402986)
38. Ribo M., J. Montaner, C. A. Molina, J. F. Arenillas, E. Santamarina, M. Quintana & J. Alvarez-Sabin: Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke, 35, 2123-7 (2004) (Pubitemid 39129572)
39. Cocho D., M. Borrell, J. Marti-Fabregas, J. Montaner, M. Castellanos, Y. Bravo, L. Molina-Porcel, R. Belvis, J. A. Diaz-Manera, A. Martinez-Domeno, M. Martinez-Lage, M. Millan, J. Fontcuberta & J. L. Marti-Vilalta: Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with Tissue Plasminogen Activator. Stroke, 37, 996-9 (2006)
40. Trouillas P., L. Derex, F. Philippeau, N. Nighoghossian, J. Honnorat, M. Hanss, P. Ffrench, P. Adeleine & M. Dechavanne: Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases. Stroke, 35, 1323-8 (2004) (Pubitemid 38697451)
41. Jauch E. C., G. F. Ross, S. Beiler, C. Beiler, T. Choudhri, & K. R. Wagner: Plasma biomarkers distinguish acute ischemic stroke patients at risk to develop intracerebral hemorrhage after thrombolytic therapy. Stroke, 37, 635 (2006)
42. Gonzalez-Conejero R., I. Fernandez-Cadenas, J. A. Iniesta, J. Marti-Fabregas, V. Obach, J. Alvarez-Sabin, V. Vicente, J. Corral & J. Montaner; Proyecto Ictus Research Group: Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke, 37, 2288-93 (2006) (Pubitemid 44337171)
43. Ribo M., J. Montaner, C. A. Molina, J. F. Arenillas, E. Santamarina & J. Alvarez-Sabin: Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost, 91, 1146-51 (2004) (Pubitemid 38821271)
44. Marti-Fabregas J, Borrell M, Cocho D, R. Belvis, M. Castellanos, J. Montaner, J. Pagonabarraga, A. Aleu, L. Molina-Porcel, J. Diaz-Manera, Y. Bravo, J. Alvarez-Sabin, A. Davalos, J. Fontcuberta & J. L. Marti-Vilalta: Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology, 65, 366-70 (2005) (Pubitemid 41099797)
45. Rubiera M., J. Alvarez-Sabin, M. Ribo, J. Montaner, E. Santamarina, J. F. Arenillas, R. Huertas, R. Delgado, F. Purroy & C. A. Molina: Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke, 36, 1452-6 (2005) (Pubitemid 40967511)
46. Foerch C., R. du Mesnil de Rochemont, O. Singer, T. Neumann-Haefelin, M. Buchkremer, F. E. Zanella, H. Steinmetz & M. Sitzer: S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion. J Neurol Neurosurg Psychiatry, 74, 322-5 (2003) (Pubitemid 36259355)
47. Heo J. H., S. H. Kim, K. Y. Lee, E. H. Kim, C. K. Chu & J. M. Nam: Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke, 34, 48-50 (2003)
48. Vila N., J. Castillo, A. Dávalos & A. Chamorro: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke, 31, 2325-9 (2000)
49. Fassbender K., S. Rossol, T. Kammer, M. Daffertshofer, S. Wirth, M. Dollman & M. Hennerici: Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome disease. J Neurol Sci, 122, 135-9 (1994) (Pubitemid 24097260)
50. Montaner J., I. Fernandez-Cadenas, C. A. Molina, M. Ribo, R. Huertas, A. Rosell, A. Penalba, L. Ortega, P. Chacon & J. Alvarez-Sabin: Post-stroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke, 37, 1205-10 (2006) (Pubitemid 43731863)
51. Gorman M. J., D. Tanne, & C. A. Lewandowski: Centenarian stroke treated with tissue-type plasminogen activator. Cerebrovasc Dis, 13, 285-7 (2002) (Pubitemid 34518725)
52. Foerch C., B. Otto, O. C. Singer, T. Neumann-Haefelin, B. Yan, J. Berkefeld, H. Steinmetz & M. Sitzer: Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke, 35, 2160-4 (2004) (Pubitemid 39129579)
53. Serena J., M. Blanco, M. Castellanos, Y. Silva, J. Vivancos, M. A. Moro, R. Leira, I. Lizasoain, J. Castillo & A. Dávalos: The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke, 36, 1921-6 (2005) (Pubitemid 41266528)